Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Polycythemia Vera Channel

Explore the latest updates and expert interviews

Welcome to The Polycythemia Vera (PV) Channel

VJHemOnc is pleased to present The Polycythemia Vera Channel, featuring interviews, podcasts, and expert-led roundtable discussions on the latest advances in this rare blood disorder.

The treatment landscape of PV has expanded to include ruxolitinib, however several investigational agents including ropeginterferon, bulsufan and hydroxyurea have demonstrated efficacy in high-risk patients with PV.

Explore the latest trial updates in PV with The Polycythemia Vera Channel, brought to you by VJHemOnc.

Can treatment-free remission become a reality in polycythemia vera? 1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
Using symptom assessment tools to improve MPN care 2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
How meaningful benefit in MPNs could evolve over the next five years 2:04
How meaningful benefit in MPNs could evolve over the next five years
Ruben Mesa • 2 Oct 2026
Insights into the current role of ropeginterferon in the ET treatment landscape 3:31
Insights into the current role of ropeginterferon in the ET treatment landscape
Lucia Masarova • 4 Oct 2026
Approaching the selection between rusfertide and interferons when treating PV: advice for clinicians 2:53
Approaching the selection between rusfertide and interferons when treating PV: advice for clinicians
Abdulraheem Yacoub • 2 Oct 2026
MPN Progression Registry: insights into the work of the MPN Research Foundation 19:15
MPN Progression Registry: insights into the work of the MPN Research Foundation
David Shoultz et al. • 2 Oct 2026
Emerging therapeutic strategies and future directions in MPNs 3:00
Emerging therapeutic strategies and future directions in MPNs
Lucia Masarova • 4 Oct 2026
Evolving treatment landscape in ET, PV, and MF: does MF still represent the greatest unmet need? 2:21
Evolving treatment landscape in ET, PV, and MF: does MF still represent the greatest unmet need?
Prithviraj Bose • 18 Sep 2026
Evolving treatment recommendations in myelofibrosis 1:35
Evolving treatment recommendations in myelofibrosis
Aaron Gerds • 21 Sep 2026
Optimizing MPN treatment strategies in community practice 1:23
Optimizing MPN treatment strategies in community practice
Aaron Gerds • 21 Sep 2026
The significance of the VERIFY trial in PV: paving the way for hepcidin mimetics and modulators 1:28
The significance of the VERIFY trial in PV: paving the way for hepcidin mimetics and modulators
Naveen Pemmaraju • 10 Sep 2026
Restore-PV trial: Phase II study of DISC-3405 in polycythemia vera 1:52
Restore-PV trial: Phase II study of DISC-3405 in polycythemia vera
Naveen Pemmaraju • 10 Sep 2026
Insights into the evolving treatment landscape for MPNs: current state and future directions 2:22
Insights into the evolving treatment landscape for MPNs: current state and future directions
Ruben Mesa • 12 Jun 2026
Rusfertide reduces cytoreductive therapy requirements in polycythemia vera 1:22
Rusfertide reduces cytoreductive therapy requirements in polycythemia vera
Francesca Palandri • 12 Jun 2026
A modern, individualized approach to managing polycythemia vera 2:30
A modern, individualized approach to managing polycythemia vera
Francesca Palandri • 12 Jun 2026
The impact of rusfertide on PV-related symptoms & patient-reported outcomes in the VERIFY trial 1:00
The impact of rusfertide on PV-related symptoms & patient-reported outcomes in the VERIFY trial
Alessandro Lucchesi • 13 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals